Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has reported new interim clinical findings suggesting that its cystic fibrosis medicine ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) may restore meaningful exocrine pancreatic function in some children aged two to five years. Data presented at the North American Cystic Fibrosis Conference in Atlanta, Georgia, showed that 18 of 48 children eligible for a pancreatic enzyme replacement therapy discontinuation substudy successfully stopped enzyme supplementation, while nearly half of those assessed reached a biomarker threshold associated with pancreatic sufficiency.
The findings, announced on October 9, 2026, extend the clinical discussion surrounding cystic fibrosis transmembrane conductance regulator (CFTR) modulators beyond respiratory outcomes and into the possibility of modifying early organ damage. Pancreatic insufficiency has historically been considered largely irreversible once established, leaving many people with cystic fibrosis dependent on pancreatic enzyme replacement therapy (PERT) to support food digestion and nutrient absorption. Vertex’s results suggest that pancreatic function may remain recoverable in some young children receiving effective CFTR modulation, although the available data do not establish that recovery will persist indefinitely.
The new evidence comes from Cohort 2 of Study VX22-121-106, an ongoing open-label extension evaluating ALYFTREK in children aged two to five. The pancreatic enzyme substudy assessed participants after at least 48 weeks of treatment, with a broader enrolled cohort of 66 children included in the company’s reporting. Importantly, ALYFTREK remains investigational for children younger than six years in the United States, where its current approved indication begins at age six and is restricted to patients meeting the specified CFTR genetic eligibility criteria.
The distinction between biomarker improvement, successful enzyme discontinuation and permanent organ recovery is central to interpreting the development. While the reported results identify a potentially important clinical benefit, the analysis is interim, uncontrolled and does not yet establish how long participants can remain independent of enzyme replacement. Those questions will become increasingly important as Vertex pursues younger pediatric populations and seeks to demonstrate benefits of earlier treatment beyond improvements in conventional respiratory and sweat chloride measurements.
What do the ALYFTREK pancreatic enzyme results reveal about recovery of exocrine function?
The most clinically significant finding concerns fecal elastase-1, a biomarker used to assess the pancreas’s ability to produce digestive enzymes. Vertex reported a mean fecal elastase-1 concentration of 239.7 micrograms per gram of stool after at least 48 weeks of ALYFTREK treatment, representing an average increase of 110.2 micrograms per gram from baseline. The company also reported that 48.6% of children in the relevant assessment reached a fecal elastase-1 concentration of at least 200 micrograms per gram, a commonly accepted threshold associated with pancreatic exocrine sufficiency.
These measurements suggest that a proportion of young children receiving ALYFTREK demonstrated meaningful improvement in pancreatic enzyme production. In cystic fibrosis, defective CFTR protein disrupts normal fluid and electrolyte transport, contributing to thickened secretions, pancreatic duct obstruction and progressive injury to enzyme-producing tissue. The resulting exocrine pancreatic insufficiency can impair digestion and nutrient absorption, making enzyme supplementation an important part of clinical management.
The improvement in fecal elastase-1 is particularly relevant because it provides a physiological measurement beyond conventional respiratory assessments. However, reaching the threshold of 200 micrograms per gram does not necessarily establish complete restoration of pancreatic health or guarantee normal digestion under every circumstance. Pancreatic function can fluctuate, and clinical interpretation must consider nutritional status, symptoms, repeated measurements and the broader medical condition of each patient.
The more direct functional finding involved 18 of the 48 children eligible for the PERT discontinuation substudy, representing 37.5%, who successfully stopped enzyme replacement. At the interim analysis, these children had remained off PERT for an average of 8.6 weeks, with individual durations ranging from 1.9 to 17.6 weeks. This result suggests that some participants had achieved sufficient improvement to discontinue an established supportive treatment during the observed period, although longer follow-up is necessary to determine whether enzyme independence can be maintained.
Vertex separately reported that seven participants had discontinued pancreatic enzyme replacement before becoming eligible for the substudy. Across the broader cohort of 66 children, 50% were not receiving PERT at the interim data cut. That overall figure describes enzyme-use status at a particular time and should not be interpreted as evidence that half of all participants stopped PERT specifically because of treatment-associated pancreatic recovery.
Why could early CFTR modulator treatment change the understanding of pancreatic damage in cystic fibrosis?
Exocrine pancreatic insufficiency is one of the earliest manifestations of cystic fibrosis, often developing during infancy as impaired CFTR activity contributes to progressive pancreatic injury. Once substantial injury has occurred, the organ may lose the ability to secrete adequate digestive enzymes, creating a long-term requirement for enzyme replacement. Historically, this process has been regarded as largely irreversible, particularly among patients with established disease.
The introduction of highly effective CFTR modulator therapies has begun challenging that assumption, especially in young children whose pancreatic tissue may retain greater functional capacity. By improving the activity of defective CFTR protein, these treatments can address an underlying biological mechanism rather than simply replacing digestive enzymes after insufficiency develops. Whether this improvement can preserve or restore pancreatic function appears to depend partly on the extent of existing damage and the age at which effective treatment begins.
Earlier evidence has already suggested that pancreatic recovery is possible in selected patients receiving CFTR modulators. A peer-reviewed study published in Pediatric Pulmonology in June 2025 examined fecal elastase-1 changes in 35 children younger than 12 who received elexacaftor/tezacaftor/ivacaftor. Seven children, representing 20% of the study population, demonstrated an increase of at least 100 micrograms per gram, supporting the possibility that some pancreatic function can improve after modulator treatment.
That earlier research is important when interpreting Vertex’s latest announcement because the possibility of pancreatic recovery is not entirely new. The ALYFTREK findings add evidence involving a different triple-combination treatment, a younger population and a substudy that specifically examined discontinuation of enzyme replacement. However, differences in patient selection, baseline pancreatic function, treatment exposure and study design mean the results cannot establish that ALYFTREK is superior to other CFTR modulators for pancreatic recovery.
The broader implication is that pancreatic outcomes may become increasingly relevant when evaluating CFTR therapies initiated early in life. For future pediatric development programmes, demonstrating improvements in digestive function, nutritional status and the need for supportive medication could provide additional evidence of clinical value beyond established measures of respiratory function.
How do the pancreatic findings build on ALYFTREK’s earlier Phase 3 pediatric results?
Vertex’s latest pancreatic analysis follows Phase 3 findings presented at the European Cystic Fibrosis Conference in June 2026. That earlier open-label study enrolled 67 children aged two to five years, all of whom completed the 24-week evaluation period. Its primary endpoint was safety and tolerability, while changes in sweat chloride concentration provided an important measure of CFTR function.
The company reported a mean sweat chloride reduction of 9.6 mmol/L from a baseline established while participants were receiving TRIKAFTA (elexacaftor/tezacaftor/ivacaftor). Approximately 92% of the children reached sweat chloride concentrations below 60 mmol/L, while 65% achieved concentrations below 30 mmol/L. The findings suggested additional improvement in the measured biological function of CFTR among children transitioning from an established highly effective modulator regimen.
Sweat chloride is an important biomarker in cystic fibrosis because abnormal chloride transport is central to the disease mechanism. Concentrations below 30 mmol/L fall within a range generally regarded as inconsistent with a cystic fibrosis diagnosis in diagnostic testing, although achieving that concentration during treatment does not mean the underlying inherited disease has been eliminated. The measurement indicates improved CFTR activity rather than a cure or proof that existing organ damage has completely resolved.
The pancreatic enzyme findings now provide a different form of evidence from the same broader pediatric development programme. While sweat chloride results demonstrate changes in CFTR function, fecal elastase-1 measurements offer an assessment of pancreatic enzyme production. Observing improvements across these biological domains strengthens the rationale for evaluating whether earlier treatment can affect several organ systems, although the reported data do not establish a direct causal relationship between a particular sweat chloride reduction and successful PERT discontinuation.
The extended observation period also adds value compared with the original 24-week study. Nevertheless, the pancreatic substudy remains open-label, and the reported results do not include a randomised comparison capable of quantifying the additional benefit attributable specifically to ALYFTREK. More complete individual-level information could help determine whether the children who achieved pancreatic sufficiency shared particular baseline characteristics or treatment-response patterns.
Can children who regain pancreatic function safely remain off enzyme replacement therapy?
The possibility of reducing or discontinuing pancreatic enzyme replacement has important implications for families managing cystic fibrosis, but successful withdrawal requires more than a single favourable laboratory measurement. Pancreatic enzyme supplementation is used to prevent malabsorption and its consequences, including poor weight gain, gastrointestinal symptoms and inadequate absorption of fat-soluble vitamins. Decisions about changing supportive treatment therefore depend on continued assessment of digestive function and nutritional health.
Clinical experience with earlier CFTR modulators has shown that some children may achieve improved fecal elastase concentrations after treatment initiation. However, published research also indicates that clinicians use different approaches when evaluating enzyme reduction, often considering repeated fecal elastase measurements, growth patterns, gastrointestinal symptoms and nutritional laboratory results. The variation reflects the limited amount of long-term evidence available for determining which patients can remain pancreatic sufficient after stopping enzyme supplementation.
The Cystic Fibrosis Foundation has recognised this evolving area in its nutritional guidance, noting that highly effective modulator therapy may improve or reverse exocrine pancreatic insufficiency in some young children. Its guidance also identifies fecal pancreatic elastase testing as potentially useful when changes in pancreatic status are clinically suspected among children up to five years of age. Such recommendations provide a framework for evaluating pancreatic function, but they do not establish that enzyme withdrawal will be appropriate for every child receiving CFTR modulator treatment.
Vertex’s reported mean duration of 8.6 weeks without PERT represents an important limitation when assessing durability. A child may initially tolerate enzyme discontinuation without obvious deterioration, while longer follow-up could reveal changes in weight, gastrointestinal symptoms or nutrient absorption. The range of observation periods in the substudy also indicates that participants had not all accumulated equivalent time without supplementation.
Future analyses will need to establish whether pancreatic sufficiency persists over longer periods and whether successful enzyme discontinuation produces sustained improvements in treatment burden without compromising nutrition. Particular attention may be warranted for children with borderline fecal elastase concentrations, variable digestive symptoms or histories of severe pancreatic insufficiency. Those longer-term outcomes will determine how meaningfully the findings can influence routine pediatric cystic fibrosis management.
What safety and regulatory questions remain before ALYFTREK can reach children younger than six?
Although ALYFTREK has been commercially available in the United States since its original FDA approval in December 2024, the medicine is not currently approved there for children younger than six. Its approved indication covers patients aged six years and older with a clinical diagnosis of cystic fibrosis and at least one CFTR gene variant that meets the specified responsiveness or protein-production criteria. The April 2026 expansion of its mutation eligibility broadened access within the approved age population without extending authorisation to younger children.
Vertex reported in August 2026 that it had initiated global regulatory submissions seeking to expand ALYFTREK’s use to children aged two to five. The October pancreatic findings may contribute to the broader understanding of the medicine’s pediatric profile, but they do not themselves constitute a regulatory approval or confirm that a particular agency has accepted every component of the age-expansion application. The ultimate decision will depend on the full clinical, pharmacological and safety evidence reviewed by the relevant authorities.
Safety assessment remains especially important because ALYFTREK carries a boxed warning concerning drug-induced liver injury and liver failure. Elevated liver enzymes have been observed with ALYFTREK, while serious liver injury, including liver failure, has been reported with TRIKAFTA, which contains related active ingredients. The approved prescribing information therefore includes requirements for liver-function assessment and ongoing monitoring.
Additional warnings address neuropsychiatric events, including suicidal thoughts and behaviours, intracranial hypertension, drug interactions and other safety considerations. These risks require careful evaluation in pediatric populations because age, developmental stage, underlying health conditions and concomitant medication may influence clinical management. The October 9 pancreatic announcement did not provide a detailed new safety analysis for the discontinuation substudy, meaning the current release should not be treated as evidence that the younger population has a completely characterised long-term safety profile.
Earlier Phase 3 findings in the two-to-five-year age group were described by Vertex as generally consistent with the medicine’s established safety profile. However, regulatory evaluation must consider the complete dataset, including adverse events, laboratory abnormalities, exposure and tolerability over time. Any future authorisation would also need to specify the approved pediatric population, formulation and dosing arrangements.
Why could the ALYFTREK findings strengthen Vertex Pharmaceuticals’ cystic fibrosis franchise?
For Vertex Pharmaceuticals Incorporated, the pancreatic recovery findings contribute to a strategy centred on improving outcomes through increasingly effective CFTR modulation and treatment initiation at younger ages. The company has developed a broad cystic fibrosis portfolio that includes TRIKAFTA and ALYFTREK, alongside earlier-generation treatments. Its commercial position is supported by therapies targeting the underlying CFTR defect rather than relying exclusively on symptom management.
The latest study adds another potential dimension to ALYFTREK’s clinical profile. A treatment that improves CFTR function while allowing some patients to reduce dependence on pancreatic enzyme replacement could offer benefits beyond conventional respiratory measures. However, such outcomes would require sustained evidence before they could be translated into formal comparative claims, reimbursement arguments or assumptions about reduced healthcare expenditure.
The company has already established significant commercial momentum around its cystic fibrosis products. In its second-quarter 2026 results, Vertex reported total revenue of $3.33 billion, representing 12% growth compared with the corresponding period in 2025. Management attributed part of the increase to continued cystic fibrosis treatment demand, including new ALYFTREK initiations and expanding uptake outside the United States.
Vertex also reported that ALYFTREK had secured reimbursement in 25 countries by the second quarter of 2026. This geographic expansion provides an existing commercial foundation for the product, although any future pediatric label extension would still depend on jurisdiction-specific regulatory and reimbursement decisions. Authorisation for younger children would broaden the potentially eligible population, but the resulting revenue contribution would depend on patient numbers, treatment switching, access and actual prescribing.
The financial significance of the pancreatic findings should also be considered proportionately. Vertex’s larger commercial opportunity remains linked to sustained use of its approved cystic fibrosis medicines, geographic expansion and development of treatments across additional therapeutic areas. The relatively small pancreatic substudy may strengthen confidence in ALYFTREK’s clinical potential, but it does not provide sufficient evidence to quantify incremental sales or justify a specific revenue forecast.
How did Vertex shares perform as investors assessed the latest ALYFTREK clinical findings?
Vertex Pharmaceuticals shares closed at $510.08 on the Nasdaq on October 9, 2026, increasing 1.36% from the previous session’s closing price of $503.25. The stock traded between $502.06 and $514.90 during the session, indicating positive movement but not an unusually large reaction relative to the company’s broader valuation. The closing price also remained below the stock’s 52-week high of $560.25, reached in early September.
The market response coincided with the ALYFTREK clinical disclosure, although the available trading information does not establish that the pancreatic findings were the principal cause of the share-price increase. Vertex has a substantial marketed pharmaceutical portfolio and several development programmes, meaning investor expectations can be influenced by multiple clinical, regulatory and commercial developments simultaneously. The latest cystic fibrosis data are therefore better understood as an incremental signal supporting the franchise’s longer-term clinical positioning rather than an immediate financial event.
Management’s latest financial guidance provides a broader reference point for investor expectations. Following the second-quarter results, Vertex increased its full-year 2026 revenue forecast to between $13.1 billion and $13.2 billion, compared with its previous guidance of $12.95 billion to $13.1 billion. The company is scheduled to report third-quarter financial results on November 2, 2026, offering investors another opportunity to assess cystic fibrosis sales momentum and the commercial contribution of ALYFTREK.
The commercial relevance of the pediatric pancreatic findings may become clearer if Vertex secures regulatory expansion and demonstrates durable reductions in enzyme dependence. Until then, the evidence supports interest in additional clinical differentiation rather than a measurable near-term earnings contribution. Investors will need to distinguish the potential scientific significance of the findings from assumptions about immediate market expansion.
What do the additional NACFC 2026 presentations reveal about Vertex’s broader research priorities?
Beyond the pancreatic enzyme substudy, Vertex presented additional research at the North American Cystic Fibrosis Conference covering long-term treatment outcomes and the broader burden associated with cystic fibrosis care. One analysis examined intravenous antibiotic use among patients aged 12 years and older receiving vanzacaftor/tezacaftor/deutivacaftor during a 96-week open-label extension. The work was described as a post-hoc analysis, meaning its findings require interpretation within the limitations of the underlying study design.
Intravenous antibiotic use is a relevant outcome in cystic fibrosis because pulmonary infections and exacerbations can create substantial treatment burdens. However, changes identified through post-hoc analyses cannot automatically establish that a medicine reduces hospitalisation, severe infections or healthcare expenditure unless the study design and supporting evidence justify those conclusions. Vertex’s October release did not provide the detailed numerical results necessary to make a quantified claim about reduced antibiotic use.
Other conference abstracts examined the natural history of exocrine pancreatic function in infants younger than 12 months and the lifetime treatment burden and cost associated with pancreatic enzyme replacement. These research areas complement the new ALYFTREK findings because they address the timing of pancreatic deterioration and the consequences of long-term supportive treatment. Understanding these factors may help researchers define when early CFTR modulation could offer the greatest potential benefit.
Nevertheless, economic research on PERT burden should not be treated as evidence that ALYFTREK has already demonstrated healthcare cost savings. Such a conclusion would require evidence of sustained enzyme independence, treatment-related expenditure, ongoing monitoring requirements and the costs associated with the CFTR modulator itself. Clinical outcomes and economic consequences must therefore be evaluated separately.
What must the next ALYFTREK studies establish before pancreatic recovery changes clinical practice?
The most consequential next step will be determining whether the improvements in fecal elastase-1 and enzyme independence persist as the children continue receiving treatment. Longer follow-up could reveal whether the initial recovery signal is stable, whether some participants require enzyme replacement again and whether early gains translate into better growth and nutritional outcomes. These findings would also help clarify whether pancreatic recovery represents a durable change in disease biology or a more variable functional response.
Larger datasets will be important for identifying potential predictors of response. Baseline pancreatic function, age at treatment initiation, CFTR genotype and prior exposure to other modulators may influence the likelihood of reaching pancreatic sufficiency. However, the interim findings do not currently establish which characteristics reliably identify children most likely to benefit, and subgroup analyses will need appropriate statistical interpretation.
Future research may also need to distinguish improved enzyme secretion from broader structural recovery of pancreatic tissue. Fecal elastase-1 provides useful evidence of exocrine function, but it does not independently demonstrate complete organ regeneration or confirm protection against all pancreatic complications. Integrating pancreatic biomarkers with nutritional assessments, clinical outcomes and longer observation periods would provide a more comprehensive understanding of the treatment’s effects.
The regulatory pathway adds a separate milestone. Vertex has initiated global submissions for ALYFTREK in the two-to-five-year age group, but the medicine remains investigational for these children in the United States as of October 11, 2026. Any approval would establish the conditions under which the treatment may be marketed for the younger population, while continued clinical evidence would determine how the pancreatic findings should influence practice.
The latest ALYFTREK results therefore offer a potentially meaningful addition to the evidence supporting early treatment of cystic fibrosis. The observation that 18 eligible children discontinued pancreatic enzyme replacement, accompanied by improvements in a recognised pancreatic function biomarker, challenges the assumption that established pancreatic insufficiency must always remain permanent. The decisive question is whether these improvements can be sustained safely and translated into lasting nutritional and clinical benefits, rather than remaining encouraging findings from an interim, uncontrolled analysis.
